The role of bispecific antibodies for oncologic therapeutics and beyond continues to grow, bringing forth a focused effort on ensuring safety without compromising efficacy. At Cambridge Healthtech Institute’s Inaugural Safety and Efficacy of Bispecific Antibodies conference, challenges around toxicity and efficacy will be discussed in the context of emerging bispecifics and ADCs. Methods of mitigating toxicity while delivering potent bispecifics and ADCs will be explored, along with considerations for the clinical development lifecycle, from CMC strategy for clinical supply through to clinical safety and efficacy. Topics such as combination therapies and strategies for achieving better risk/benefit profiles to address currently unmet needs will be covered. The meeting seeks to complement topics in bispecific antibody discovery and engineering by honing in on clinical challenges and successes.